PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32979233-0	2021	9The PI3Kgamma/AKT signaling pathway mediates peripheral antinociceptive action of dipyrone.	Dipyrone	83-91	AKT serine/threonine kinase 1	Rattus norvegicus	15-18
32979233-5	2021	Herein, we investigated the role of the PI3Kgamma/AKT signaling cascade in the context of peripheral analgesic effect of DIP.	Dipyrone	121-124	AKT serine/threonine kinase 1	Rattus norvegicus	50-53
32979233-9	2021	Consistently, AKT selective inhibitor also reversed analgesic DIP effects.	Dipyrone	62-65	AKT serine/threonine kinase 1	Rattus norvegicus	14-17
32979233-10	2021	Corroborating these data, we found that DIP induced AKT phosphorylation in cultured dorsal root ganglion neurons, which was prevented in the presence of PI3Kgamma selective inhibitor.	Dipyrone	40-43	AKT serine/threonine kinase 1	Rattus norvegicus	52-55
32979233-11	2021	Taken together, these findings provide evidence that peripheral analgesic effect of DIP is dependent on the activation of PI3Kgamma/AKT signaling pathway.	Dipyrone	84-87	AKT serine/threonine kinase 1	Rattus norvegicus	132-135
33675325-0	2021	NAT2 polymorphisms as a cause of metamizole-induced agranulocytosis.	Dipyrone	33-43	N-acetyltransferase 2	Homo sapiens	0-4
33675325-7	2021	For all patients, pharmacogenetic diagnostic for the genes CYP2C9, CYP2C19 and NAT2, which are involved in metamizole metabolism and degradation of toxic metabolites, was initiated.	Dipyrone	107-117	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	59-65
33675325-7	2021	For all patients, pharmacogenetic diagnostic for the genes CYP2C9, CYP2C19 and NAT2, which are involved in metamizole metabolism and degradation of toxic metabolites, was initiated.	Dipyrone	107-117	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	67-74
33675325-7	2021	For all patients, pharmacogenetic diagnostic for the genes CYP2C9, CYP2C19 and NAT2, which are involved in metamizole metabolism and degradation of toxic metabolites, was initiated.	Dipyrone	107-117	N-acetyltransferase 2	Homo sapiens	79-83
33675325-14	2021	In conclusion, metamizole-induced agranulocytosis most likely was a consequence of the underlying genetical predisposition, that is, polymorphisms in the genes NAT2, CYP2C9 and CYP2C19.	Dipyrone	15-25	N-acetyltransferase 2	Homo sapiens	160-164
33675325-14	2021	In conclusion, metamizole-induced agranulocytosis most likely was a consequence of the underlying genetical predisposition, that is, polymorphisms in the genes NAT2, CYP2C9 and CYP2C19.	Dipyrone	15-25	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	166-172
33675325-14	2021	In conclusion, metamizole-induced agranulocytosis most likely was a consequence of the underlying genetical predisposition, that is, polymorphisms in the genes NAT2, CYP2C9 and CYP2C19.	Dipyrone	15-25	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	177-184
33094670-3	2021	We review several drugs (isoniazid, hydralazine, sulfamethazine, amifampridine, procainamide, sulfasalazine, amonafide and metamizole for which NAT2 phenotype-guided therapy may be important.	Dipyrone	123-133	N-acetyltransferase 2	Homo sapiens	144-148
32652557-9	2021	CONCLUSION: Our findings support preliminary evidence that metamizole acts as a potent inductor of cytochrome P450 isoenzymes CYP2B6 and CYP3A4.	Dipyrone	59-69	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	126-132
32652557-9	2021	CONCLUSION: Our findings support preliminary evidence that metamizole acts as a potent inductor of cytochrome P450 isoenzymes CYP2B6 and CYP3A4.	Dipyrone	59-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	137-143
33257279-13	2021	CONCLUSIONS: Dipyrone at both doses and meloxicam provided a nonselective inhibition of COX-1 and -2 activities and effective analgesia without causing significant adverse effects or laboratory tests alterations.	Dipyrone	13-21	cytochrome c oxidase subunit I	Felis catus	88-100
31490743-0	2020	Computational Analysis of Dipyrone Metabolite 4-Aminoantipyrine as a Cannabinoid Receptor 1 Agonist.	Dipyrone	26-34	cannabinoid receptor 1	Homo sapiens	69-91
32562269-0	2020	CB1 receptor-dependent TRPV1 desensitisation contributes to the analgesic effect of dipyrone in sensitised primary sensory neurons.	Dipyrone	84-92	cannabinoid receptor 1	Homo sapiens	0-3
32562269-0	2020	CB1 receptor-dependent TRPV1 desensitisation contributes to the analgesic effect of dipyrone in sensitised primary sensory neurons.	Dipyrone	84-92	transient receptor potential cation channel subfamily V member 1	Homo sapiens	23-28
32562269-2	2020	Recently we have reported that the dipyrone metabolite 4-aminoantipirine (4-AA) reduces prostaglandin E2 (PGE2 )-induced pain-related behaviour through the cannabinoid type 1 (CB1) receptor.	Dipyrone	35-43	cannabinoid receptor 1	Homo sapiens	176-179
32059848-6	2020	Dipyrone induced endogenous Bdnf expression by Ca2+ influx evoked via L-type voltage-dependent Ca2+ channels and the N-methyl-d-aspartate receptor, indicating that dipyrone induced activity-regulated Bdnf expression in neurons.	Dipyrone	0-8	brain derived neurotrophic factor	Homo sapiens	200-204
32059848-6	2020	Dipyrone induced endogenous Bdnf expression by Ca2+ influx evoked via L-type voltage-dependent Ca2+ channels and the N-methyl-d-aspartate receptor, indicating that dipyrone induced activity-regulated Bdnf expression in neurons.	Dipyrone	164-172	brain derived neurotrophic factor	Homo sapiens	28-32
32059848-6	2020	Dipyrone induced endogenous Bdnf expression by Ca2+ influx evoked via L-type voltage-dependent Ca2+ channels and the N-methyl-d-aspartate receptor, indicating that dipyrone induced activity-regulated Bdnf expression in neurons.	Dipyrone	164-172	brain derived neurotrophic factor	Homo sapiens	200-204
32059848-7	2020	However, dipyrone-induced Bdnf expression is independent of validated pharmacological effects.	Dipyrone	9-17	brain derived neurotrophic factor	Homo sapiens	26-30
32691345-9	2020	Simultaneously, our findings provide evidence that metamizole diminishes the expression of pronociceptive interleukins (IL-1beta, IL-6, and IL-18) and chemokines (CCL2, CCL4, and CCL7) in DRG measured 7 days after sciatic nerve injury.	Dipyrone	51-61	interleukin 1 alpha	Rattus norvegicus	120-128
32691345-9	2020	Simultaneously, our findings provide evidence that metamizole diminishes the expression of pronociceptive interleukins (IL-1beta, IL-6, and IL-18) and chemokines (CCL2, CCL4, and CCL7) in DRG measured 7 days after sciatic nerve injury.	Dipyrone	51-61	interleukin 6	Rattus norvegicus	130-134
32691345-9	2020	Simultaneously, our findings provide evidence that metamizole diminishes the expression of pronociceptive interleukins (IL-1beta, IL-6, and IL-18) and chemokines (CCL2, CCL4, and CCL7) in DRG measured 7 days after sciatic nerve injury.	Dipyrone	51-61	interleukin 18	Rattus norvegicus	140-145
32691345-9	2020	Simultaneously, our findings provide evidence that metamizole diminishes the expression of pronociceptive interleukins (IL-1beta, IL-6, and IL-18) and chemokines (CCL2, CCL4, and CCL7) in DRG measured 7 days after sciatic nerve injury.	Dipyrone	51-61	C-C motif chemokine ligand 2	Rattus norvegicus	163-167
32691345-9	2020	Simultaneously, our findings provide evidence that metamizole diminishes the expression of pronociceptive interleukins (IL-1beta, IL-6, and IL-18) and chemokines (CCL2, CCL4, and CCL7) in DRG measured 7 days after sciatic nerve injury.	Dipyrone	51-61	C-C motif chemokine ligand 4	Rattus norvegicus	169-173
32691345-9	2020	Simultaneously, our findings provide evidence that metamizole diminishes the expression of pronociceptive interleukins (IL-1beta, IL-6, and IL-18) and chemokines (CCL2, CCL4, and CCL7) in DRG measured 7 days after sciatic nerve injury.	Dipyrone	51-61	C-C motif chemokine ligand 7	Rattus norvegicus	179-183
32057719-0	2020	Dipyrone is locally hydrolyzed to 4-methylaminoantipyrine and its antihyperalgesic effect depends on CB2 and kappa-opioid receptors activation.	Dipyrone	0-8	cannabinoid receptor 2	Rattus norvegicus	101-104
32057719-3	2020	Here, were investigate the involvement of peripheral cannabinoid CB2 and opioid receptor activation in the local antihyperalgesic effect of dipyrone and 4-MAA.	Dipyrone	140-148	cannabinoid receptor 2	Rattus norvegicus	65-68
32057719-11	2020	These data suggest that the local analgesic effect of dipyrone is mediated by its hydrolyzed bioactive form, 4-MAA and, at least in part, depends on CB2 receptor and kappa-opioid receptor activation.	Dipyrone	54-62	cannabinoid receptor 2	Rattus norvegicus	149-161
32059848-0	2020	Identifying inducers of BDNF gene expression from pharmacologically validated compounds; antipyretic drug dipyrone increases BDNF mRNA in neurons.	Dipyrone	106-114	brain derived neurotrophic factor	Homo sapiens	24-28
32059848-0	2020	Identifying inducers of BDNF gene expression from pharmacologically validated compounds; antipyretic drug dipyrone increases BDNF mRNA in neurons.	Dipyrone	106-114	brain derived neurotrophic factor	Homo sapiens	125-129
32059848-5	2020	Unexpectedly, the screening assay identified the antipyretic drug, dipyrone, to increase Bdnf expression.	Dipyrone	67-75	brain derived neurotrophic factor	Homo sapiens	89-93
32059848-6	2020	Dipyrone induced endogenous Bdnf expression by Ca2+ influx evoked via L-type voltage-dependent Ca2+ channels and the N-methyl-d-aspartate receptor, indicating that dipyrone induced activity-regulated Bdnf expression in neurons.	Dipyrone	0-8	brain derived neurotrophic factor	Homo sapiens	28-32
31915847-1	2020	PURPOSE: Metamizole can sterically inhibit aspirin (ASA) from binding to cyclooxygenase 1 (COX1).	Dipyrone	9-19	prostaglandin-endoperoxide synthase 1	Homo sapiens	73-89
31915847-1	2020	PURPOSE: Metamizole can sterically inhibit aspirin (ASA) from binding to cyclooxygenase 1 (COX1).	Dipyrone	9-19	prostaglandin-endoperoxide synthase 1	Homo sapiens	91-95
31490743-3	2020	Recently it was shown some evidence of a dipyrone metabolite acting over the Cannabinoid Receptor 1.	Dipyrone	41-49	cannabinoid receptor 1	Homo sapiens	77-99
31490743-4	2020	OBJECTIVE: Our goal here is to explore the dipyrone metabolite 4-aminoantipyrine as a Cannabinoid Receptor 1 agonist, reviewing dipyrone characteristics, and investigating the structural basis for its interaction with Cannabinoid Receptor 1.	Dipyrone	43-51	cannabinoid receptor 1	Homo sapiens	86-108
31490743-4	2020	OBJECTIVE: Our goal here is to explore the dipyrone metabolite 4-aminoantipyrine as a Cannabinoid Receptor 1 agonist, reviewing dipyrone characteristics, and investigating the structural basis for its interaction with Cannabinoid Receptor 1.	Dipyrone	43-51	cannabinoid receptor 1	Homo sapiens	218-240
31490743-5	2020	METHOD: We reviewed here recent functional studies related to the dipyrone metabolite focusing on its action as a Cannabinoid Receptor 1 agonist.	Dipyrone	66-74	cannabinoid receptor 1	Homo sapiens	114-136
31490743-9	2020	The mechanistic analysis and the present computational study suggest that the dipyrone metabolite 4-aminoantipyrine interacts with Cannabinoid Receptor 1.	Dipyrone	78-86	cannabinoid receptor 1	Homo sapiens	131-153
31583344-0	2019	Active metabolites of dipyrone induce a redox-dependent activation of the ion channels TRPA1 and TRPV1.	Dipyrone	22-30	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	87-92
31583344-4	2019	In this study, we explored the effects of dipyrone and its active metabolites on recombinant and native TRPA1 and TRPV1 channels.	Dipyrone	42-50	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	114-119
31583344-0	2019	Active metabolites of dipyrone induce a redox-dependent activation of the ion channels TRPA1 and TRPV1.	Dipyrone	22-30	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	97-102
31583344-3	2019	In mice, however, the analgesic effect of dipyrone also seems to depend on the ion channel TRPA1.	Dipyrone	42-50	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	91-96
31583344-4	2019	In this study, we explored the effects of dipyrone and its active metabolites on recombinant and native TRPA1 and TRPV1 channels.	Dipyrone	42-50	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	104-109
30094229-4	2018	Results: In the observed period, utilization of metamizole was 3.31 fold higher in Serbia than in Croatia (median in Serbia was 2.238 vs. 0.675 in Croatia DDD/1,000 inhabitants/per day/per year).	Dipyrone	48-58	keratin 5	Homo sapiens	155-160
30652827-6	2019	Since studies in humans and animals have demonstrated the presence of beta2-adrenoceptors in biliary tract smooth muscle and beta2-adrenoceptor activation has been shown to occur in dipyrone-induced delayed GE, it is likely that this kind of receptors may participate in the reduction of smooth muscle spasm of the sphincter of Oddi induced by dipyrone.	Dipyrone	182-190	adrenoceptor beta 2	Homo sapiens	70-88
30267794-5	2018	We observed that metamizol influences the spinal levels of the nociceptin receptor (NOP) but does not alter the expression of other members of the opioid receptor family (mu (MOP), delta (DOP) and kappa (KOP)), or other important nociception receptors (transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1)).	Dipyrone	17-26	opioid receptor-like 1	Mus musculus	63-82
30267794-5	2018	We observed that metamizol influences the spinal levels of the nociceptin receptor (NOP) but does not alter the expression of other members of the opioid receptor family (mu (MOP), delta (DOP) and kappa (KOP)), or other important nociception receptors (transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1)).	Dipyrone	17-26	opioid receptor-like 1	Mus musculus	84-87
27600926-0	2016	Keep in Mind TRPA1 When Prescribing Metamizole!	Dipyrone	36-46	transient receptor potential cation channel subfamily A member 1	Homo sapiens	13-18
29436141-0	2018	Reply to Ziesenitz, Victoria; Erb Thomas; Trachsel, Daniel; van den Anker Johannes, regarding their comment "Safety of dipryone (metamizole) in children-what"s the risk of agranulocytosis?"	Dipyrone	129-139	estrogen receptor 2	Homo sapiens	30-33
27812963-3	2017	Carbamazepine and metamizole metabolites N-acetyl-4-amino-antipyrine (4-AAA) and N-formyl-4-amino-antipyrine (4-FAA) have the highest frequency of occurrence in surface water (57.3-68.8 %) and in groundwater (19.5-43.9 %), respectively.	Dipyrone	18-28	FA complementation group A	Homo sapiens	112-115
28416926-4	2017	RESULTS: When used alone, dipyrone and losartan inhibited Phe, KCl, and Ang II-induced contractions, whereas lisinopril inhibited only Phe and Ang II-induced contractions.	Dipyrone	26-34	angiotensinogen	Rattus norvegicus	72-78
28416926-5	2017	Inhibition of COX enzymes (COX-3, COX-3 + COX-1, COX-1+ COX-2 + COX-3 by dipyrone 10-4, 7 x 10-4, 2 x 10-3 M, respectively) augmented the relaxant effects of losartan or lisinopril.	Dipyrone	73-81	cytochrome c oxidase III, mitochondrial	Rattus norvegicus	27-32
28416926-5	2017	Inhibition of COX enzymes (COX-3, COX-3 + COX-1, COX-1+ COX-2 + COX-3 by dipyrone 10-4, 7 x 10-4, 2 x 10-3 M, respectively) augmented the relaxant effects of losartan or lisinopril.	Dipyrone	73-81	cytochrome c oxidase III, mitochondrial	Rattus norvegicus	34-39
28416926-5	2017	Inhibition of COX enzymes (COX-3, COX-3 + COX-1, COX-1+ COX-2 + COX-3 by dipyrone 10-4, 7 x 10-4, 2 x 10-3 M, respectively) augmented the relaxant effects of losartan or lisinopril.	Dipyrone	73-81	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	49-54
28416926-5	2017	Inhibition of COX enzymes (COX-3, COX-3 + COX-1, COX-1+ COX-2 + COX-3 by dipyrone 10-4, 7 x 10-4, 2 x 10-3 M, respectively) augmented the relaxant effects of losartan or lisinopril.	Dipyrone	73-81	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	56-61
28416926-5	2017	Inhibition of COX enzymes (COX-3, COX-3 + COX-1, COX-1+ COX-2 + COX-3 by dipyrone 10-4, 7 x 10-4, 2 x 10-3 M, respectively) augmented the relaxant effects of losartan or lisinopril.	Dipyrone	73-81	cytochrome c oxidase III, mitochondrial	Rattus norvegicus	34-39
27551180-0	2016	IgE-Mediated Reaction to Metamizole: Evaluation of a Patient with Severe Anaphylaxis.	Dipyrone	25-35	immunoglobulin heavy constant epsilon	Homo sapiens	0-3
27525093-0	2016	GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier"s gangrene and severe septic shock in an adolescent.	Dipyrone	40-50	colony stimulating factor 2	Homo sapiens	0-6
27525093-0	2016	GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier"s gangrene and severe septic shock in an adolescent.	Dipyrone	52-60	colony stimulating factor 2	Homo sapiens	0-6
25749766-0	2015	Basophil Activation Tests Based on CD193 Marker in Dipyrone Allergy.	Dipyrone	51-59	C-C motif chemokine receptor 3	Homo sapiens	35-40
26840714-11	2016	These results suggest that beta2-adrenoceptor activation occurred in delayed liquid gastric emptying induced by the phenylpyrazole derivatives dipyrone, 4-aminoantipyrine, and antipyrine.	Dipyrone	143-151	adrenoceptor beta 2	Rattus norvegicus	27-45
25557763-6	2015	Both CB1 and TRPV1 blockade reversed these effects, suggesting that the endocannabinoid/endovanilloid system takes part in the analgesic effects of dipyrone.	Dipyrone	148-156	cannabinoid receptor 1 (brain)	Mus musculus	5-8
25154757-7	2015	Cystatin C and creatinine levels remained comparable in patients treated with acetaminophen and dipyrone.	Dipyrone	96-104	cystatin C	Homo sapiens	0-10
25430877-0	2015	Cannabinoid CB1 receptors mediate the effects of dipyrone.	Dipyrone	49-57	cannabinoid receptor 1	Homo sapiens	12-15
25430877-14	2015	These results indicate involvement of the endocannabinoid system, especially CB1 receptors, in the analgesic and cataleptic effects of dipyrone, as well as hypolocomotion.	Dipyrone	135-143	cannabinoid receptor 1	Homo sapiens	77-80
25765567-0	2015	The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives.	Dipyrone	51-59	transient receptor potential cation channel subfamily A member 1	Homo sapiens	4-9
25765567-7	2015	In line with recent results obtained with TRPA1 antagonists and TRPA1 gene deletion, the two most largely used PDs, dipyrone and propyphenazone, attenuated TRPA1-mediated nociception and mechanical allodynia in models of inflammatory and neuropathic pain (formalin, carrageenan, partial sciatic nerve ligation and the chemotherapeutic drug, bortezomib).	Dipyrone	116-124	transient receptor potential cation channel subfamily A member 1	Homo sapiens	64-69
25765567-7	2015	In line with recent results obtained with TRPA1 antagonists and TRPA1 gene deletion, the two most largely used PDs, dipyrone and propyphenazone, attenuated TRPA1-mediated nociception and mechanical allodynia in models of inflammatory and neuropathic pain (formalin, carrageenan, partial sciatic nerve ligation and the chemotherapeutic drug, bortezomib).	Dipyrone	116-124	transient receptor potential cation channel subfamily A member 1	Homo sapiens	64-69
26065593-13	2015	Metamizole inhibited COX-2 gene expression at a dose of 500 mg/kg in the carrageenan test.	Dipyrone	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	21-26
26065593-14	2015	At doses of 250 and 500 mg/kg, metamizole reduced COX-2 and MPO gene expressions and oxidative stress induced by scalpel incision or carrageenan.	Dipyrone	31-41	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	50-55
26065593-14	2015	At doses of 250 and 500 mg/kg, metamizole reduced COX-2 and MPO gene expressions and oxidative stress induced by scalpel incision or carrageenan.	Dipyrone	31-41	myeloperoxidase	Rattus norvegicus	60-63
25557763-6	2015	Both CB1 and TRPV1 blockade reversed these effects, suggesting that the endocannabinoid/endovanilloid system takes part in the analgesic effects of dipyrone.	Dipyrone	148-156	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	13-18
25467825-0	2015	Contribution of nociceptin/orphanin FQ receptors to the anti-nociceptive and hypothermic effects of dipyrone.	Dipyrone	100-108	prepronociceptin	Mus musculus	27-38
25467825-5	2015	OBJECTIVE: Investigation of the role of the N/OFQ system in paracetamol-induced anti-nociception and hypothermia led us to determine its role in the anti-nociceptive and hypothermic effects of dipyrone.	Dipyrone	193-201	prepronociceptin	Mus musculus	44-49
24338284-10	2014	The non-steroid anti-inflammatory drug metamizole also reversed completely the action of IL-1beta (187-207).	Dipyrone	39-49	interleukin 1 beta	Rattus norvegicus	89-97
25058903-3	2014	The aim of this study was to investigate the participation of peripheral CB1 and CB2 cannabinoid receptors activation in the anti-hyperalgesic effect of dipyrone, 4-MAA or 4-AA.	Dipyrone	153-161	cannabinoid receptor 1	Rattus norvegicus	73-76
25058903-3	2014	The aim of this study was to investigate the participation of peripheral CB1 and CB2 cannabinoid receptors activation in the anti-hyperalgesic effect of dipyrone, 4-MAA or 4-AA.	Dipyrone	153-161	cannabinoid receptor 2	Rattus norvegicus	81-84
25058903-9	2014	AM251 or ODN anti-sense against neuronal CB1 receptor, but not AM630, reversed the anti-hyperalgesic effect mediated by 4-AA, but not by dipyrone or 4-MAA.	Dipyrone	137-145	cannabinoid receptor 1	Rattus norvegicus	41-44
25241292-0	2014	Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole.	Dipyrone	86-96	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	22-27
25241292-0	2014	Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole.	Dipyrone	86-96	N-acetyltransferase 2	Homo sapiens	32-36
25222785-5	2014	However, the effects and the mechanisms of dipyrone and 2,5-dimethylcelecoxib on tumour necrosis factor (TNF)-alpha and Th1- and Th2-related chemokines in monocytes remain poorly defined.	Dipyrone	43-51	tumor necrosis factor	Homo sapiens	81-115
25222785-6	2014	This study was carried out to investigate the effects of dipyrone and 2,5-dimethylcelecoxib on the expression of Th1 (IP-10) and Th2 (I-309 and MDC) and TNF-alpha in human monocytes and the associated intracellular mechanism.	Dipyrone	57-65	C-X-C motif chemokine ligand 10	Homo sapiens	118-123
25222785-6	2014	This study was carried out to investigate the effects of dipyrone and 2,5-dimethylcelecoxib on the expression of Th1 (IP-10) and Th2 (I-309 and MDC) and TNF-alpha in human monocytes and the associated intracellular mechanism.	Dipyrone	57-65	C-C motif chemokine ligand 22	Homo sapiens	144-147
25222785-6	2014	This study was carried out to investigate the effects of dipyrone and 2,5-dimethylcelecoxib on the expression of Th1 (IP-10) and Th2 (I-309 and MDC) and TNF-alpha in human monocytes and the associated intracellular mechanism.	Dipyrone	57-65	tumor necrosis factor	Homo sapiens	153-162
25222785-11	2014	RESULTS: Dipyrone and 2,5-dimethylcelecoxib downregulated LPS-induced Th2-related chemokine I-309 and macrophage derived chemokine (MDC) production.	Dipyrone	9-17	C-C motif chemokine ligand 22	Homo sapiens	102-130
25222785-11	2014	RESULTS: Dipyrone and 2,5-dimethylcelecoxib downregulated LPS-induced Th2-related chemokine I-309 and macrophage derived chemokine (MDC) production.	Dipyrone	9-17	C-C motif chemokine ligand 22	Homo sapiens	132-135
25222785-14	2014	Dipyrone and 2,5-dimethylcelecoxib suppressed LPS-induced p65 and JNK MAPK (C-Jun N-terminal kinase mitogen activated protein kinase).	Dipyrone	0-8	RELA proto-oncogene, NF-kB subunit	Homo sapiens	58-61
25222785-14	2014	Dipyrone and 2,5-dimethylcelecoxib suppressed LPS-induced p65 and JNK MAPK (C-Jun N-terminal kinase mitogen activated protein kinase).	Dipyrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	66-69
25222785-16	2014	INTERPRETATION & CONCLUSIONS: Dipyrone and 2,5-dimethylcelecoxib downregulated LPS-induced Th2-related chemokine I-309 and MDC in THP-1 cells.	Dipyrone	34-42	C-C motif chemokine ligand 22	Homo sapiens	127-130
24512007-0	2014	Metamizole-induced bicytopenia reversed by G-CSF and IVIG treatment in a child.	Dipyrone	0-10	colony stimulating factor 3	Homo sapiens	43-48
24086771-10	2013	Otherwise, either dipyrone or pregabalin (both 30 mg/kg) did not significantly affect the paw edema or the depressive-like behaviour induced by CFA, whereas the oral treatment with dipyrone (300 mg/kg) was able to reduce the immobility time in TST.	Dipyrone	181-189	thiosulfate sulfurtransferase, mitochondrial	Mus musculus	244-247
23784345-0	2013	Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone.	Dipyrone	74-82	cannabinoid receptor 1 (brain)	Mus musculus	27-30
22954646-3	2012	Two novel arachidonoyl-conjugated metabolites are formed in mice following the administration of dipyrone that are dependent on the activity of fatty acid amide hydrolase (FAAH), which also represents the major catabolic enzyme of the endogenous cannabinoid ligand anandamide.	Dipyrone	97-105	fatty acid amide hydrolase	Mus musculus	155-170
22519658-1	2012	AIMS: This study aimed to investigate the effect of metamizole on bupropion hydroxylation related to different CYP2B6 genotype groups in healthy volunteers.	Dipyrone	52-62	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	111-117
22519658-10	2012	CONCLUSIONS: Oral administration of metamizole for 4 days significantly altered the pharmacokinetics of both bupropion and its active metabolite, 4-hydroxybupropion, and significantly increased the CYP2B6-catalyzed bupropion hydroxylation in all of the subjects.	Dipyrone	36-46	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	198-204
23409047-0	2013	CREBH determines the severity of sulpyrine-induced fatal shock.	Dipyrone	33-42	cAMP responsive element binding protein 3-like 3	Mus musculus	0-5
23409047-3	2013	Here, we report that the transcription factor CREBH that is highly expressed in the liver plays an important role in fatal shock induced by sulpyrine in mice.	Dipyrone	140-149	cAMP responsive element binding protein 3-like 3	Mus musculus	46-51
23409047-4	2013	CREBH-deficient mice were resistant to experimental fatal sulpyrine shock.	Dipyrone	58-67	cAMP responsive element binding protein 3-like 3	Mus musculus	0-5
23409047-5	2013	We found that sulpyrine-induced expression of cytochrome P450 2B (CYP2B) family genes, which are involved in sulpyrine metabolism, in the liver was severely impaired in CREBH-deficient mice.	Dipyrone	14-23	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	46-64
23409047-5	2013	We found that sulpyrine-induced expression of cytochrome P450 2B (CYP2B) family genes, which are involved in sulpyrine metabolism, in the liver was severely impaired in CREBH-deficient mice.	Dipyrone	14-23	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	66-71
23409047-5	2013	We found that sulpyrine-induced expression of cytochrome P450 2B (CYP2B) family genes, which are involved in sulpyrine metabolism, in the liver was severely impaired in CREBH-deficient mice.	Dipyrone	14-23	cAMP responsive element binding protein 3-like 3	Mus musculus	169-174
23409047-5	2013	We found that sulpyrine-induced expression of cytochrome P450 2B (CYP2B) family genes, which are involved in sulpyrine metabolism, in the liver was severely impaired in CREBH-deficient mice.	Dipyrone	109-118	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	46-64
23409047-5	2013	We found that sulpyrine-induced expression of cytochrome P450 2B (CYP2B) family genes, which are involved in sulpyrine metabolism, in the liver was severely impaired in CREBH-deficient mice.	Dipyrone	109-118	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	66-71
23409047-5	2013	We found that sulpyrine-induced expression of cytochrome P450 2B (CYP2B) family genes, which are involved in sulpyrine metabolism, in the liver was severely impaired in CREBH-deficient mice.	Dipyrone	109-118	cAMP responsive element binding protein 3-like 3	Mus musculus	169-174
23409047-6	2013	Moreover, introduction of CYP2B in CREBH-deficient liver restored susceptibility to sulpyrine.	Dipyrone	84-93	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	26-31
23409047-6	2013	Moreover, introduction of CYP2B in CREBH-deficient liver restored susceptibility to sulpyrine.	Dipyrone	84-93	cAMP responsive element binding protein 3-like 3	Mus musculus	35-40
23409047-7	2013	Furthermore, ectopic expression of CREBH up-regulated CYP2B10 promoter activity, and in vivo knockdown of CREBH in wild-type mice conferred a significant resistance to fatal sulpyrine shock.	Dipyrone	174-183	cAMP responsive element binding protein 3-like 3	Mus musculus	35-40
23409047-7	2013	Furthermore, ectopic expression of CREBH up-regulated CYP2B10 promoter activity, and in vivo knockdown of CREBH in wild-type mice conferred a significant resistance to fatal sulpyrine shock.	Dipyrone	174-183	cAMP responsive element binding protein 3-like 3	Mus musculus	106-111
23409047-8	2013	These data demonstrate that CREBH is a positive regulator of CYP2B in response to sulpyrine administration, which possibly results in fatal shock.	Dipyrone	82-91	cAMP responsive element binding protein 3-like 3	Mus musculus	28-33
23409047-8	2013	These data demonstrate that CREBH is a positive regulator of CYP2B in response to sulpyrine administration, which possibly results in fatal shock.	Dipyrone	82-91	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	61-66
22954646-3	2012	Two novel arachidonoyl-conjugated metabolites are formed in mice following the administration of dipyrone that are dependent on the activity of fatty acid amide hydrolase (FAAH), which also represents the major catabolic enzyme of the endogenous cannabinoid ligand anandamide.	Dipyrone	97-105	fatty acid amide hydrolase	Mus musculus	172-176
22954646-5	2012	The relative contributions of cannabinoid receptors and FAAH in the overall behavioral response to dipyrone remain untested.	Dipyrone	99-107	fatty acid amide hydrolase	Mus musculus	56-60
22954646-6	2012	Accordingly, the two primary objectives of the present study were to determine whether the behavioral effects of dipyrone would (a) be blocked by cannabinoid receptor antagonists and (b) occur in FAAH mice.	Dipyrone	113-121	fatty acid amide hydrolase	Mus musculus	196-200
22337336-8	2012	In both cases, the antinociceptive effect of metamizol was reduced by a microinjection of AM251, an antagonist at the CB1 cannabinoid receptor, either into the LVL-PAG or into the rostral ventromedial medulla (RVM).	Dipyrone	45-54	cannabinoid receptor 1	Rattus norvegicus	118-121
22905592-0	2012	IgE-mediated metamizol allergy and the usefulness of the cellular allergen stimulation test.	Dipyrone	13-22	immunoglobulin heavy constant epsilon	Homo sapiens	0-3
22905592-10	2012	Skin tests proved to be a good diagnostic method to identify IgE-mediated metamizol allergy, although skin tests elicited systemic symptoms in some cases.	Dipyrone	74-83	immunoglobulin heavy constant epsilon	Homo sapiens	61-64
22337336-10	2012	These results show that endocannabinoids and their CB1 receptor (1) contribute at the LVL-PAG to the antinociceptive effects of metamizol, and possibly other non-opioid analgesics; and (2) participate in the PAG-derived activation of RVM descending antinociceptive influences.	Dipyrone	128-137	cannabinoid receptor 1	Rattus norvegicus	51-54
21133897-2	2011	For a better understanding of the mechanisms by which dipyrone exerts antipyresis, we have investigated its effects on fever and changes in PGE(2) content in plasma, CSF and hypothalamus induced by either LPS or ET-1.	Dipyrone	54-62	endothelin 1	Rattus norvegicus	212-216
21552169-2	2011	We recently identified dipyrone as an antiapoptotic agent by screening a library of 1040 compounds for their ability to inhibit cytochrome c release from isolated mitochondria.	Dipyrone	23-31	cytochrome c, somatic	Homo sapiens	128-140
21552169-6	2011	Dipyrone inhibited the release of cytochrome c and other mitochondrial apoptogenic factors from mitochondria into the cytoplasm, and attenuated subsequent caspase-9 and caspase-3 activation both in vitro and in vivo.	Dipyrone	0-8	cytochrome c, somatic	Homo sapiens	34-46
21552169-6	2011	Dipyrone inhibited the release of cytochrome c and other mitochondrial apoptogenic factors from mitochondria into the cytoplasm, and attenuated subsequent caspase-9 and caspase-3 activation both in vitro and in vivo.	Dipyrone	0-8	caspase 9	Homo sapiens	155-164
21552169-6	2011	Dipyrone inhibited the release of cytochrome c and other mitochondrial apoptogenic factors from mitochondria into the cytoplasm, and attenuated subsequent caspase-9 and caspase-3 activation both in vitro and in vivo.	Dipyrone	0-8	caspase 3	Homo sapiens	169-178
21552169-7	2011	Moreover, dipyrone prevented ischemia-induced changes in Bcl-2 and tBid, and ameliorated oxygen/glucose deprivation-mediated loss of mitochondrial membrane potential.	Dipyrone	10-18	BCL2 apoptosis regulator	Homo sapiens	57-62
21537904-12	2012	The vasodilatory activities of bradykinin and des-Arg9-bradykinin were significantly increased upon the inhibition of COX-3 (dipyrone at 100 muM).	Dipyrone	125-133	cytochrome c oxidase III, mitochondrial	Rattus norvegicus	118-123
21133897-11	2011	Dipyrone abolished both the fever and the increased CSF PGE(2) levels induced by LPS or ET-1 but did not affect the increased hypothalamic PGE(2) levels.	Dipyrone	0-8	endothelin 1	Rattus norvegicus	88-92
19003845-5	2008	We found that dopamine amides of fenamic acids have TRPV1 agonist activity in the nanomolar range, and that the arachidonoyl amide of a dipyrone metabolite has TRPV1 antagonist activity.	Dipyrone	136-144	transient receptor potential cation channel subfamily V member 1	Homo sapiens	160-165
20884738-0	2010	N-acetyltransferase 2 polymorphisms and susceptibility to infant leukemia with maternal exposure to dipyrone during pregnancy.	Dipyrone	100-108	N-acetyltransferase 2	Homo sapiens	0-21
20884738-2	2010	N-Acetyltransferase 2 (NAT2) enzyme acetylates dipyrone, resulting in a detoxified metabolite.	Dipyrone	47-55	N-acetyltransferase 2	Homo sapiens	0-21
20884738-2	2010	N-Acetyltransferase 2 (NAT2) enzyme acetylates dipyrone, resulting in a detoxified metabolite.	Dipyrone	47-55	N-acetyltransferase 2	Homo sapiens	23-27
20884738-7	2010	Unconditional logistic regression was used to examine the association between maternal exposure to dipyrone during the index pregnancy, IL, and NAT2 phenotypes.	Dipyrone	99-107	N-acetyltransferase 2	Homo sapiens	144-148
20884738-10	2010	An association between IL and NAT2 phenotype was observed in IL whether the mothers reported dipyrone exposures (OR, 4.48; 95% CI, 1.88-10.7) or not (OR, 4.27; 95% CI, 1.75-10.5).	Dipyrone	93-101	N-acetyltransferase 2	Homo sapiens	30-34
19697962-5	2009	We found that the number of motifs which describe the colocalization of 5-lipoxygenase (5-LO) or 12-LO with other proteins increased disproportionally after dipyrone treatment.	Dipyrone	157-165	arachidonate 5-lipoxygenase	Mus musculus	72-86
14990791-3	2004	In the present study, it was shown that the blockade was caused by a specific PKG inhibitor (KT5823) of the antinociceptive effect of morphine and dipyrone on acute hypernociception and of dipyrone on persistent hypernociception.	Dipyrone	147-155	protein kinase cGMP-dependent 1	Homo sapiens	78-81
18157167-1	2008	BACKGROUND AND PURPOSE: The analgesics, paracetamol and dipyrone are weak inhibitors of the cyclooxygenase isoforms 1 or 2 (COX-1, COX-2) but more potent on COX-3.	Dipyrone	56-64	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	124-129
18157167-1	2008	BACKGROUND AND PURPOSE: The analgesics, paracetamol and dipyrone are weak inhibitors of the cyclooxygenase isoforms 1 or 2 (COX-1, COX-2) but more potent on COX-3.	Dipyrone	56-64	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	131-136
18157167-1	2008	BACKGROUND AND PURPOSE: The analgesics, paracetamol and dipyrone are weak inhibitors of the cyclooxygenase isoforms 1 or 2 (COX-1, COX-2) but more potent on COX-3.	Dipyrone	56-64	cytochrome c oxidase III, mitochondrial	Rattus norvegicus	157-162
18236017-14	2007	With respect to gastric MPO activity, dipyrone caused a decrease in the histamine-induced ulcer group but it caused an increase in the stress-induced and DDC-induced ulcer groups.	Dipyrone	38-46	myeloperoxidase	Rattus norvegicus	24-27
17344806-2	2007	Analysis of liver microsomes from patients treated with metamizole revealed selectively higher expression of cytochromes P450, CYP2B6 and CYP3A4 (3.8- and 2.8-fold, respectively), and 2.9-fold higher bupropion hydroxylase activity compared with untreated subjects.	Dipyrone	56-66	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	127-133
17344806-2	2007	Analysis of liver microsomes from patients treated with metamizole revealed selectively higher expression of cytochromes P450, CYP2B6 and CYP3A4 (3.8- and 2.8-fold, respectively), and 2.9-fold higher bupropion hydroxylase activity compared with untreated subjects.	Dipyrone	56-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-144
16156402-9	2005	The combined use of CAST and BAT in metamizol allergy detects 76% of the cases and 76.9% when associating the skin tests.	Dipyrone	36-45	calpastatin	Homo sapiens	20-24
15494191-0	2004	Involvement of cholecystokinin in the opioid tolerance induced by dipyrone (metamizol) microinjections into the periaqueductal gray matter of rats.	Dipyrone	66-74	cholecystokinin	Rattus norvegicus	15-30
15494191-0	2004	Involvement of cholecystokinin in the opioid tolerance induced by dipyrone (metamizol) microinjections into the periaqueductal gray matter of rats.	Dipyrone	76-85	cholecystokinin	Rattus norvegicus	15-30
15494191-5	2004	Microinjection of cholecystokinin (1 ng/0.5 microl) into PAG blocked the antinociceptive effect of a subsequent microinjection of dipyrone (150 microg/0.5 microl) into the same site, as evaluated by the tail flick and hot plate tests.	Dipyrone	130-138	cholecystokinin	Rattus norvegicus	18-33
15494191-8	2004	These results suggest that PAG-microinjected dipyrone triggers and/or potentiates local opioidergic circuits leading to descending inhibition of nociception, on the one hand, and to a local antiopioid action by cholecystokinin, on the other.	Dipyrone	45-53	cholecystokinin	Rattus norvegicus	211-226
15494191-9	2004	Reiteration of these events would then result in an enhancement of cholecystokinin"s antiopioid action and thus tolerance to opioids and dipyrone in the PAG.	Dipyrone	137-145	cholecystokinin	Rattus norvegicus	67-82
17944992-6	2008	RESULTS: 4-Methylaminoantipyrine (MAA), the active metabolite of dipyrone, largely attenuated or even completely abolished the inhibition of arachidonic acid-induced platelet aggregation, thromboxane formation and P-selectin expression by aspirin.	Dipyrone	65-73	selectin P	Homo sapiens	214-224
17435173-11	2007	Given the profound COX-2 suppression by dipyrone, which was considerably above COX-2 inhibition by single analgesic doses of celecoxib and rofecoxib, a significant portion of its analgesic action may be ascribed to peripheral mechanisms.	Dipyrone	40-48	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	19-24
17435173-12	2007	In view of the observed COX-1 suppression, physicochemical factors (lack of acidity) rather than differential COX-1 inhibition may be responsible for dipyrone"s favorable gastrointestinal tolerability compared with acidic COX inhibitors.	Dipyrone	150-158	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	24-29
17627114-2	2007	An explanation for this difference in pharmacologic activity was provided by the recent discovery of a new cyclooxygenase isoform, cyclooxygenase (COX)-3, that is reported to be inhibited by phenacetin, acetaminophen and dipyrone.	Dipyrone	221-229	cytochrome c oxidase III, mitochondrial	Rattus norvegicus	131-153
15958287-0	2005	Metamizol acts as an ATP sensitive potassium channel opener to inhibit the contracting response induced by angiotensin II but not to norepinephrine in rat thoracic aorta smooth muscle.	Dipyrone	0-9	angiotensinogen	Rattus norvegicus	107-121
15958287-13	2005	Our results suggest that MZ induces relaxation and inhibits contraction induced by AT II acting as a K(ATP) opener.	Dipyrone	25-27	angiotensinogen	Rattus norvegicus	83-88
15107131-3	2004	Aim of this study was to examine the influence of the COX-1 inhibiting NSAIDs, diclofenac and metamizol on platelet activation and leukocyte-platelet complexes, in vitro.	Dipyrone	94-103	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	54-59
14990791-3	2004	In the present study, it was shown that the blockade was caused by a specific PKG inhibitor (KT5823) of the antinociceptive effect of morphine and dipyrone on acute hypernociception and of dipyrone on persistent hypernociception.	Dipyrone	189-197	protein kinase cGMP-dependent 1	Homo sapiens	78-81
14722642-8	2004	C-reactive protein increased over time, but compared to the other groups it was significantly lower in patients receiving metamizol after 4 h. Cytokine concentrations were not different among the three groups or over time, although interleukin 6 tended to decrease over time in the metamizol group.	Dipyrone	122-131	C-reactive protein	Homo sapiens	0-18
14722642-8	2004	C-reactive protein increased over time, but compared to the other groups it was significantly lower in patients receiving metamizol after 4 h. Cytokine concentrations were not different among the three groups or over time, although interleukin 6 tended to decrease over time in the metamizol group.	Dipyrone	282-291	interleukin 6	Homo sapiens	232-245
12708979-0	2003	Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients.	Dipyrone	100-109	CD63 molecule	Homo sapiens	7-11
14592545-5	2003	COX-3, a variant of COX-1, has been found in canine brain and is inhibited by acetaminophen and dipyrone at physiological concentrations.	Dipyrone	96-104	cytochrome c oxidase subunit III	Canis lupus familiaris	0-5
14592545-5	2003	COX-3, a variant of COX-1, has been found in canine brain and is inhibited by acetaminophen and dipyrone at physiological concentrations.	Dipyrone	96-104	cytochrome c oxidase subunit I	Canis lupus familiaris	20-25
12927630-5	2003	TNF evoked a time- and dose-dependent muscle hyperalgesia within several hours after injection that was totally reversed by systemic treatment with the non-opioid analgesic metamizol.	Dipyrone	173-182	tumor necrosis factor	Rattus norvegicus	0-3
12242329-12	2002	Comparison of canine COX-3 activity with murine COX-1 and -2 demonstrates that this enzyme is selectively inhibited by analgesic/antipyretic drugs such as acetaminophen, phenacetin, antipyrine, and dipyrone, and is potently inhibited by some nonsteroidal antiinflammatory drugs.	Dipyrone	198-206	cytochrome c oxidase subunit III	Canis lupus familiaris	21-26
12242329-12	2002	Comparison of canine COX-3 activity with murine COX-1 and -2 demonstrates that this enzyme is selectively inhibited by analgesic/antipyretic drugs such as acetaminophen, phenacetin, antipyrine, and dipyrone, and is potently inhibited by some nonsteroidal antiinflammatory drugs.	Dipyrone	198-206	cytochrome c oxidase I, mitochondrial	Mus musculus	48-60
11440730-0	2001	Effects of metamizol and magnesium sulfate on enzyme activity of glucose 6-phosphate dehydrogenase from human erythrocyte in vitro and rat erythrocyte in vivo.	Dipyrone	11-20	glucose-6-phosphate dehydrogenase	Homo sapiens	65-98
11710546-4	2001	The cytoprotective effect of dipyrone is associated with a decrease in DNA fragmentation, as assessed by electrophoresis of genomic DNA and by flow cytometry; a reduction in the percentage of condensed nuclei, as evaluated by DNA staining with Hoescht 33342 and a decrease in poly(ADP)-ribose polymerase (PARP) cleavage, as assessed by Western blotting.	Dipyrone	29-37	poly(ADP-ribose) polymerase 1	Homo sapiens	276-303
11710546-4	2001	The cytoprotective effect of dipyrone is associated with a decrease in DNA fragmentation, as assessed by electrophoresis of genomic DNA and by flow cytometry; a reduction in the percentage of condensed nuclei, as evaluated by DNA staining with Hoescht 33342 and a decrease in poly(ADP)-ribose polymerase (PARP) cleavage, as assessed by Western blotting.	Dipyrone	29-37	poly(ADP-ribose) polymerase 1	Homo sapiens	305-309
12234055-11	2002	cGMP levels were not influenced with diclofenac treatment, nevertheless metamizol reduced the nucleotide levels, which was accompanied by an inhibition of constitutive NOS (cNOS) activity without modifying the mRNA expression of the enzyme.	Dipyrone	72-81	nitric oxide synthase 3	Rattus norvegicus	155-171
12234055-11	2002	cGMP levels were not influenced with diclofenac treatment, nevertheless metamizol reduced the nucleotide levels, which was accompanied by an inhibition of constitutive NOS (cNOS) activity without modifying the mRNA expression of the enzyme.	Dipyrone	72-81	nitric oxide synthase 3	Rattus norvegicus	173-177
12234055-12	2002	CONCLUSIONS: In addition to inhibition of PG synthesis, damage induced by metamizol was associated with an inhibition of the NO/cGMP pathway and cNOS activity.	Dipyrone	74-83	nitric oxide synthase 3	Rattus norvegicus	145-149
11852909-6	2002	RESULTS: Indomethacin or dipyrone reduced LPS, IL-1beta, IL-6 or TNF-alpha induced fever and CRH release from rat hypothalamus.	Dipyrone	25-33	interleukin 1 beta	Rattus norvegicus	47-55
11852909-6	2002	RESULTS: Indomethacin or dipyrone reduced LPS, IL-1beta, IL-6 or TNF-alpha induced fever and CRH release from rat hypothalamus.	Dipyrone	25-33	interleukin 6	Rattus norvegicus	57-61
11852909-6	2002	RESULTS: Indomethacin or dipyrone reduced LPS, IL-1beta, IL-6 or TNF-alpha induced fever and CRH release from rat hypothalamus.	Dipyrone	25-33	tumor necrosis factor	Rattus norvegicus	65-74
11852909-6	2002	RESULTS: Indomethacin or dipyrone reduced LPS, IL-1beta, IL-6 or TNF-alpha induced fever and CRH release from rat hypothalamus.	Dipyrone	25-33	corticotropin releasing hormone	Rattus norvegicus	93-96
11852909-11	2002	Dipyrone at a very high concentration (10 mM) inhibited only COX-1, while indomethacin (0.1 microM) blocked COX-1 and COX-2 in COS-7 cells.	Dipyrone	0-8	COX1	Chlorocebus aethiops	61-66
11440730-1	2001	OBJECTIVE: Effects of metamizol and magnesium sulfate on erythrocyte glucose 6-phosphate dehydrogenase enzyme activity were investigated in in vitro and in vivo conditions.	Dipyrone	22-31	glucose-6-phosphate dehydrogenase	Homo sapiens	69-102
11440730-7	2001	CONCLUSION: The results of this study suggested that metamizol and magnesium sulfate have significant inhibition effect on the activity of glucose 6-phosphate dehydrogenase enzyme in both in vivo and in vitro.	Dipyrone	53-62	glucose-6-phosphate dehydrogenase	Homo sapiens	139-172
10987821-3	2000	Surprisingly, administration of analgesic doses of morphine or the nonsteroidal antiinflammatory drugs aspirin, metamizol (dipyrone), and indomethacin also increased GPDH mRNA levels in rat spinal cord.	Dipyrone	112-121	glycerol-3-phosphate dehydrogenase 1	Rattus norvegicus	166-170
11484831-9	2001	Erythrocyte CAT activity was increased by Na-salicylate, acemetacin, and tenoxicam at the therapeutic, and by dipyrone at the high concentration.	Dipyrone	110-118	catalase	Homo sapiens	12-15
10987821-3	2000	Surprisingly, administration of analgesic doses of morphine or the nonsteroidal antiinflammatory drugs aspirin, metamizol (dipyrone), and indomethacin also increased GPDH mRNA levels in rat spinal cord.	Dipyrone	123-131	glycerol-3-phosphate dehydrogenase 1	Rattus norvegicus	166-170
10336004-6	1999	While cefotaxime-dependent antibody was directed against CD16, the metamizole antibody was directed against CD11b and CD35.	Dipyrone	67-77	integrin subunit alpha M	Homo sapiens	108-113
10493111-1	1999	The ability of metamizol to inhibit cyclooxygenase-1 and cyclooxygenase-2 activities has been evaluated using different cyclooxygenase sources.	Dipyrone	15-24	prostaglandin-endoperoxide synthase 1	Homo sapiens	36-52
10493111-1	1999	The ability of metamizol to inhibit cyclooxygenase-1 and cyclooxygenase-2 activities has been evaluated using different cyclooxygenase sources.	Dipyrone	15-24	prostaglandin-endoperoxide synthase 2	Homo sapiens	57-73
10493111-2	1999	Metamizol inhibited purified cyclooxygenase-1 and cyclooxygenase-2 with an IC50 of about 150 microg/ml.	Dipyrone	0-9	prostaglandin-endoperoxide synthase 1	Homo sapiens	29-45
10493111-2	1999	Metamizol inhibited purified cyclooxygenase-1 and cyclooxygenase-2 with an IC50 of about 150 microg/ml.	Dipyrone	0-9	prostaglandin-endoperoxide synthase 2	Homo sapiens	50-66
10493111-4	1999	Consistent with these findings, molecular models of the complexes between cyclooxygenase-1 or cyclooxygenase-2 with 4-methylaminoantipyrine, the major active derivative of metamizol, suggested a common binding mode to both isoforms.	Dipyrone	172-181	prostaglandin-endoperoxide synthase 1	Homo sapiens	74-90
10493111-4	1999	Consistent with these findings, molecular models of the complexes between cyclooxygenase-1 or cyclooxygenase-2 with 4-methylaminoantipyrine, the major active derivative of metamizol, suggested a common binding mode to both isoforms.	Dipyrone	172-181	prostaglandin-endoperoxide synthase 2	Homo sapiens	94-110
10493111-6	1999	The IC50 values of metamizol for cyclooxygenase-1 in intact bovine aortic endothelial cells (BAEC) cells and human platelets were 1730 +/- 150 microg/ml and 486 +/- 56 microg/ml, respectively.	Dipyrone	19-28	prostaglandin-endoperoxide synthase 1	Bos taurus	33-49
10493111-9	1999	The data presented here also indicate that cyclooxygenase-2 inhibition could play an important role in the pharmacological effects of metamizol.	Dipyrone	134-143	prostaglandin-endoperoxide synthase 2	Homo sapiens	43-59
10492062-2	1999	OBJECTIVE: To evaluate the effect of short-term administration of dipyrone on steady state CSA pharmacokinetics.	Dipyrone	66-74	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	91-94
10492062-6	1999	RESULTS: CSA concentrations over time were reduced after dipyrone (ANOVA, P < 0.01), but statistical significance was noted only at 2, 4, 5 and 10 h after drug intake (P < 0.05).	Dipyrone	57-65	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	9-12
10492062-9	1999	CONCLUSIONS: Short-term administration of dipyrone is associated with a mild decrease in CSA blood concentration, which is most prominent in the first few hours after drug intake.	Dipyrone	42-50	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	89-92
10336004-6	1999	While cefotaxime-dependent antibody was directed against CD16, the metamizole antibody was directed against CD11b and CD35.	Dipyrone	67-77	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	118-122
8378861-8	1993	In the CHDM, allergic or pseudoallergic reactions were observed in 0.23% of patients exposed to minor analgesics (including ASA preparations on a daily dose up to 1.0 g and pyrazolones, mainly metamizole, propyphenazone) and in 0.81% of patients exposed to NSAIDs (including the pyrazolone oxyphenbutazone).	Dipyrone	193-203	CHDM	Homo sapiens	7-11
12799982-6	1998	Still, it appears that high doses of the vitamins B1, B6, and B12 administered separately or in combination can alleviate acute pain and potentiate the analgesia caused by non-opioid analgesics such as the NSAIDs and metamizol (dipyrone).	Dipyrone	217-226	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	62-65
12799982-6	1998	Still, it appears that high doses of the vitamins B1, B6, and B12 administered separately or in combination can alleviate acute pain and potentiate the analgesia caused by non-opioid analgesics such as the NSAIDs and metamizol (dipyrone).	Dipyrone	228-236	NADH:ubiquinone oxidoreductase subunit B3	Homo sapiens	62-65
7942328-10	1994	IL-1 beta raised body temperature by 1.20 +/- 0.10 degrees C. An increased dose of dipyrone (50 mg/kg, i.v.)	Dipyrone	83-91	interleukin 1 beta	Rattus norvegicus	0-9
9698203-0	1998	Metamizol potentiates morphine effects on visceral pain and evoked c-Fos immunoreactivity in spinal cord.	Dipyrone	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	67-72
9698203-3	1998	Potentiation by metamizol was also observed as a bilateral decrease in stimulus-evoked c-Fos induction in superficial laminas (I-II) of the dorsal spinal cord after drug combination compared to single administration (66.5 +/- 2.2 vs. 80.7 +/- 4.2; P < 0.05).	Dipyrone	16-25	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	87-92
8845208-12	1996	The induction pattern as well as inhibition by the Mabs convincingly demonstrate the predominant production of CYP2B1/2 in the induction spectrum of dipyrone.	Dipyrone	149-157	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	111-117
8504533-2	1993	From studies in vitro, we found significant interference by dipyrone (P < 0.05) in the determination of creatine kinase (CK), lactate dehydrogenase (LD), uric acid, triglycerides, cholesterol, aspartate aminotransferase, alanine aminotransferase, and urea nitrogen with both instruments, and in the determination of creatinine in the Ektachem analyzer.	Dipyrone	60-68	glutamic--pyruvic transaminase	Homo sapiens	224-248
34270988-13	2021	Our results showed that there were no changes in AEA, 2-AG, PEA, OAE levels in the amygdala in mice exposed to chronic unpredictable mild stress model; dipyrone exerted antidepressant and anxiolytic effects at doses of 300 and 600 mg/kg; its anxiolytic effect appears to be mediated via CB1 receptors, whereas TRPV1 receptors seems to mediate its antidepressant action.	Dipyrone	152-160	cannabinoid receptor 1 (brain)	Mus musculus	287-290
1808966-1	1991	Caffeine is mainly metabolized by 3-methylcholanthreneinducible cytochrome P-450, whereas metamizol (Analgin) is probably mainly metabolized by the phenobarbital inducible cytochrome P-450 family.	Dipyrone	90-99	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	172-188
1808966-2	1991	Therefore the elimination of caffeine from serum and the elimination of the main metabolites of metamizol in urine reflect the activity of these two cytochrome P-450 families.	Dipyrone	96-105	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	149-165
2174528-4	1990	Once the residual hypersensitivity had been abolished with dipyrone or N-methyl morphine, a small dose of prostaglandin E2, dopamine or Interleukin-1 beta, which in normal animals causes a mild and short lived effect, restored the persistent hypersensitive state.	Dipyrone	59-67	interleukin 1 beta	Rattus norvegicus	136-154
2220168-2	1990	Therefore the elimination of caffeine from serum and the amount of the main metabolites of metamizol excreted into urine reflect the activity of these two cytochrome P-450 families.	Dipyrone	91-100	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	155-171
34779255-6	2022	CCK increased body temperature by ~0.4 C from 10 min post-infusion, which was attenuated by metamizol.	Dipyrone	92-101	cholecystokinin	Rattus norvegicus	0-3
34779255-7	2022	CCK reduced the number of c-Fos-positive cells in the median preoptic area (by ~70%) but increased it in the dorsal hypothalamic area and in the rostral raphe pallidus (by ~50% in both); all these changes were all completely blocked with metamizol.	Dipyrone	238-247	cholecystokinin	Rattus norvegicus	0-3
34779255-7	2022	CCK reduced the number of c-Fos-positive cells in the median preoptic area (by ~70%) but increased it in the dorsal hypothalamic area and in the rostral raphe pallidus (by ~50% in both); all these changes were all completely blocked with metamizol.	Dipyrone	238-247	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	26-31
34746007-17	2021	BMB indicated a numerically lower CD4+ to CD8+ T cells ratio in patients with irNeutropenia than in those with metamizole-induced neutropenia.	Dipyrone	111-121	CD4 molecule	Homo sapiens	34-37
34746007-17	2021	BMB indicated a numerically lower CD4+ to CD8+ T cells ratio in patients with irNeutropenia than in those with metamizole-induced neutropenia.	Dipyrone	111-121	CD8a molecule	Homo sapiens	42-45
34648192-6	2022	In the clinical study, we investigated the influence of ciprofloxacin (CYP1A2 inhibitor), fluconazole (CYP2C19 inhibitor) and the combination ciprofloxacin/fluconazole on the pharmacokinetics of metamizole in n=12 male subjects in a randomized, placebo-controlled, double-blind study.	Dipyrone	195-205	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	103-110
34270988-0	2021	The role of endocannabinoid system and TRPV1 receptors in the antidepressant and anxiolytic effects of dipyrone in chronic unpredictable mild stress in mice.	Dipyrone	103-111	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	39-44
34270988-4	2021	In this study, we aimed to investigate whether endocannabinoid levels change in the amygdala in chronic unpredictable mild stress model in mice and whether cannabinoid and TRPV1 receptors mediate antidepressant and anxiolytic effects of dipyrone.	Dipyrone	237-245	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	172-177
1623899-5	1992	Metamizole significantly reduced furosemide clearance (175 vs 141 ml.min-1), furosemide-stimulated plasma renin activity (1.42 vs 0.79 ng AI.ml-1.h-1) and the urinary excretion of prostacyclin metabolites and of prostaglandin F2 alpha (by 70-81%).	Dipyrone	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	69-74
34648192-0	2022	Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4-methylaminoantipyrine.	Dipyrone	79-89	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	0-19
34180377-11	2021	Results from immunocytochemical analysis showed a rise in the expression of caspase 8 and cytochrome C when cells were exposed to dipyrone.	Dipyrone	130-138	caspase-8	Chlorocebus sabaeus	76-85
34180377-11	2021	Results from immunocytochemical analysis showed a rise in the expression of caspase 8 and cytochrome C when cells were exposed to dipyrone.	Dipyrone	130-138	cytochrome c	Chlorocebus sabaeus	90-102
34451927-6	2021	The PMA was diminished by the TRPA1 antagonists HC-030031, A-967079, metamizole and propyphenazone and was absent in TRPA1-deficient mice.	Dipyrone	69-79	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	30-35
3671445-2	1987	From the elimination velocity of these model substances conclusions concerning the activity of 3-methylcholanthrene (caffeine elimination) and phenobarbital inducible isoenzymes (metamizol elimination) of cytochrome P-450 are drawn.	Dipyrone	179-188	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	205-221
2744732-5	1989	Only 15% of patients given dipyrone had elevated levels of these two enzymes (p less than 0.01 for ALT and p less than 0.02 for AST).	Dipyrone	27-35	solute carrier family 17 member 5	Homo sapiens	128-131
2585009-6	1989	This may explain some of the large regional odds ratio variation for dipyrone-related agranulocytosis in the International Agranulocytosis and Aplastic Anemia Study (JAMA 1986; 256: 1749-1757.	Dipyrone	69-77	F11 receptor	Homo sapiens	166-170
2903041-1	1988	After accidental re-exposure to metamizole a 50-year-old patient developed severe jaundice within five hours (total bilirubin 43.9 mg/dl) with a rise of GOT to 147, of GPT to 222, of gamma-GT to 380 and of alkaline phosphatase to 497 U/l.	Dipyrone	32-42	glutamic--pyruvic transaminase	Homo sapiens	168-171
3991787-1	1985	Caffeine is mainly metabolized by 3-methylcholanthrene-inducible cytochrome P-450 (P-450MC) and noramidopyrine-methanesulfonate sodium (metamizol, Analgin) is mainly metabolized by phenobarbital-inducible cytochrome P-450 (P-450PB).	Dipyrone	96-134	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	223-230
3552586-7	1986	Half-lives vary from 1 to 2 hours with propyphenazone, to about 7 hours with dipyrone (2 hours for the active metabolite of dipyrone, 4-methylaminoantipyrine, MAA).	Dipyrone	77-85	MAA	Homo sapiens	159-162
3552586-7	1986	Half-lives vary from 1 to 2 hours with propyphenazone, to about 7 hours with dipyrone (2 hours for the active metabolite of dipyrone, 4-methylaminoantipyrine, MAA).	Dipyrone	124-132	MAA	Homo sapiens	159-162
4095132-1	1985	Caffeine is mainly metabolized by 3-methylcholanthrene-inducible cytochrome P-450 (P-450MC) and metamizol (noramidopyrine methanesulfonate sodium) is mainly metabolized by phenobarbital-inducible cytochrome P-450 (P-450PB).	Dipyrone	107-145	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	214-221
4095132-2	1985	That"s why the half life of caffeine and the elimination of the main metabolites of metamizol were used as parameters in vivo characterizing both groups of the cytochrome P-450-complex.	Dipyrone	84-93	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-176
4095131-0	1985	[Elimination of caffeine and metamizol in in vivo characterization of cytochrome P-450 dependent biotransformation reactions in aged humans].	Dipyrone	29-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
4095131-2	1985	From the elimination velocity of these model substances conclusions concerning the activity of 3-methylcholanthrene inducible (caffeine elimination) and of phenobarbital inducible (metamizol elimination) isoenzymes of cytochrome P-450 are drawn.	Dipyrone	181-190	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	218-234
4095132-1	1985	Caffeine is mainly metabolized by 3-methylcholanthrene-inducible cytochrome P-450 (P-450MC) and metamizol (noramidopyrine methanesulfonate sodium) is mainly metabolized by phenobarbital-inducible cytochrome P-450 (P-450PB).	Dipyrone	96-105	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	214-221
2938410-0	1985	Inhibitory action of dipyrone on rat thyroid peroxidase and lactoperoxidase activities.	Dipyrone	21-29	lactoperoxidase	Rattus norvegicus	60-75
2938410-5	1985	Inhibition of peroxidase activity (Triiodide assay) was found when crude rat peroxidase preparations and LPO were incubated with dipyrone in concentrations ranging from 10(-3) M to 10(-8) M, with a Ki of 2.5 X 10(-5) M and 4 X 10(-5) M respectively.	Dipyrone	129-137	lactoperoxidase	Rattus norvegicus	105-108
2938410-7	1985	Line weaver-Burk: plots were used to investigate the inhibition of LPO activity by dipyrone.	Dipyrone	83-91	lactoperoxidase	Rattus norvegicus	67-70
3991787-1	1985	Caffeine is mainly metabolized by 3-methylcholanthrene-inducible cytochrome P-450 (P-450MC) and noramidopyrine-methanesulfonate sodium (metamizol, Analgin) is mainly metabolized by phenobarbital-inducible cytochrome P-450 (P-450PB).	Dipyrone	136-145	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	223-230
14341617-0	1964	THE ANTAGONISTIC EFFECT OF NORAMIDOPYRINE METHANESULFONATE ON SOME PHARMACOLOGICAL ACTIONS OF THE SYNTHETIC BRADYKININ.	Dipyrone	27-58	kininogen 1	Homo sapiens	108-118
33336382-0	2021	Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2.	Dipyrone	0-10	nuclear receptor subfamily 1 group I member 3	Homo sapiens	57-89
33336382-0	2021	Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2.	Dipyrone	0-10	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	114-120
33336382-2	2021	Previous studies have shown that metamizole induces cytochrome (CYP) 2B6 and possibly CYP3A4.	Dipyrone	33-43	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	52-72
33336382-2	2021	Previous studies have shown that metamizole induces cytochrome (CYP) 2B6 and possibly CYP3A4.	Dipyrone	33-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-92
33336382-5	2021	In addition, we investigated whether metamizole induces CYPs by an interaction with the constitutive androstane receptor (CAR) or the pregnane X receptor (PXR) in HepaRG cells.	Dipyrone	37-47	nuclear receptor subfamily 1 group I member 3	Homo sapiens	88-120
33336382-5	2021	In addition, we investigated whether metamizole induces CYPs by an interaction with the constitutive androstane receptor (CAR) or the pregnane X receptor (PXR) in HepaRG cells.	Dipyrone	37-47	nuclear receptor subfamily 1 group I member 3	Homo sapiens	122-125
33336382-6	2021	In the clinical study, we confirmed a moderate induction of CYP2B6 (decrease in the efavirenz AUC by 79%) and 3A4 (decrease in the midazolam AUC by 68%) by metamizole.	Dipyrone	156-166	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	60-66
33336382-7	2021	In addition, metamizole weakly induced CYP2C9 (decrease in the flurbiprofen AUC by 22%) and moderately CYP2C19 (decrease in the omeprazole AUC by 66%) but did not alter CYP2D6 activity.	Dipyrone	13-23	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	39-45
33336382-7	2021	In addition, metamizole weakly induced CYP2C9 (decrease in the flurbiprofen AUC by 22%) and moderately CYP2C19 (decrease in the omeprazole AUC by 66%) but did not alter CYP2D6 activity.	Dipyrone	13-23	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	103-110
33336382-8	2021	In addition, metamizole weakly inhibited CYP1A2 activity (1.79-fold increase in the caffeine AUC).	Dipyrone	13-23	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	41-47
33336382-9	2021	We confirmed these results in HepaRG cells, where 4-MAA, the principal metabolite of metamizole, induced the mRNA expression of CYP2B6, 2C9, 2C19 and 3A4.	Dipyrone	85-95	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	128-134
33336382-11	2021	In conclusion, metamizole is a broad CYP inducer by an interaction with CAR and an inhibitor of CYP1A2.	Dipyrone	15-25	peptidylprolyl isomerase G	Homo sapiens	37-40
33336382-11	2021	In conclusion, metamizole is a broad CYP inducer by an interaction with CAR and an inhibitor of CYP1A2.	Dipyrone	15-25	nuclear receptor subfamily 1 group I member 3	Homo sapiens	72-75
33336382-11	2021	In conclusion, metamizole is a broad CYP inducer by an interaction with CAR and an inhibitor of CYP1A2.	Dipyrone	15-25	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	96-102
33890704-1	2021	We investigated the effect of deglucuronidation on the plasma concentration of the constituents of the Basel phenotyping cocktail and on the interpretation of the phenotyping results under basal conditions and after cytochrome P450 (CYP) induction with metamizole.	Dipyrone	253-263	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	216-231
33890704-6	2021	Treatment with metamizole, a CAR-dependent inducer of CYP2B6, CYP2C9, CYP2C19 and CYP3A4, accentuated the effect of deglucuronidation on AUC and MR.	Dipyrone	15-25	CXADR pseudogene 1	Homo sapiens	29-32
33890704-6	2021	Treatment with metamizole, a CAR-dependent inducer of CYP2B6, CYP2C9, CYP2C19 and CYP3A4, accentuated the effect of deglucuronidation on AUC and MR.	Dipyrone	15-25	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	54-60
33890704-6	2021	Treatment with metamizole, a CAR-dependent inducer of CYP2B6, CYP2C9, CYP2C19 and CYP3A4, accentuated the effect of deglucuronidation on AUC and MR.	Dipyrone	15-25	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	62-68
33890704-6	2021	Treatment with metamizole, a CAR-dependent inducer of CYP2B6, CYP2C9, CYP2C19 and CYP3A4, accentuated the effect of deglucuronidation on AUC and MR.	Dipyrone	15-25	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	70-77
33890704-6	2021	Treatment with metamizole, a CAR-dependent inducer of CYP2B6, CYP2C9, CYP2C19 and CYP3A4, accentuated the effect of deglucuronidation on AUC and MR.	Dipyrone	15-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88